Lemborexant 25 mg

DRUG2 trials

Sponsors

Eisai Inc., Brendan Lucey

Conditions

Alzheimer DiseaseHealthy SubjectsObstructive Sleep Apnea

Phase 1

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

CompletedNCT03471871

Eisai Inc.Healthy Subjects, Obstructive Sleep Apnea

Start: 2018-02-21End: 2018-08-03Updated: 2020-02-17

Phase 2

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

WithdrawnNCT05728736

Brendan LuceyAlzheimer Disease

Start: 2023-03-01End: 2023-10-04Updated: 2023-11-08

Related Papers

Effect of lemborexant on sleep parameters and architecture in adult and elderly participants with mild-to-severe obstructive sleep apnea.

2025-08-18

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

Journal of Sleep Research2024-09-123 citations

0364 The Effect of Lemborexant on Polysomnographic Sleep Parameters in Adults with Mild, Moderate, or Severe Obstructive Sleep Apnea

SLEEP2023-05-01